Instilling confidence in ImmuneOnco's bispecific
The first data are dribbled out, but cross-trial comparisons look uninspiring.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Cardiff's questionable plan yields more questions
More data from onvansertib's phase 2 study fail to convince.
